ZA200107628B - Bacterial membrane fractions with adjuvant effect. - Google Patents
Bacterial membrane fractions with adjuvant effect. Download PDFInfo
- Publication number
- ZA200107628B ZA200107628B ZA200107628A ZA200107628A ZA200107628B ZA 200107628 B ZA200107628 B ZA 200107628B ZA 200107628 A ZA200107628 A ZA 200107628A ZA 200107628 A ZA200107628 A ZA 200107628A ZA 200107628 B ZA200107628 B ZA 200107628B
- Authority
- ZA
- South Africa
- Prior art keywords
- antigen
- hapten
- membrane fraction
- membrane
- complex
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 70
- 230000001580 bacterial effect Effects 0.000 title claims description 15
- 230000000240 adjuvant effect Effects 0.000 title description 2
- 239000000427 antigen Substances 0.000 claims abstract description 66
- 102000036639 antigens Human genes 0.000 claims abstract description 66
- 108091007433 antigens Proteins 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 24
- 241000894006 Bacteria Species 0.000 claims abstract description 23
- 230000004044 response Effects 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 230000028993 immune response Effects 0.000 claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 11
- 241000588747 Klebsiella pneumoniae Species 0.000 claims abstract description 10
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 7
- 239000008188 pellet Substances 0.000 claims description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 21
- 238000005119 centrifugation Methods 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 16
- 239000000725 suspension Substances 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000005859 coupling reaction Methods 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 230000008878 coupling Effects 0.000 claims description 9
- 238000010168 coupling process Methods 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 8
- 108091006027 G proteins Proteins 0.000 claims description 7
- 102000030782 GTP binding Human genes 0.000 claims description 7
- 108091000058 GTP-Binding Proteins 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 108010071390 Serum Albumin Proteins 0.000 claims description 5
- 102000007562 Serum Albumin Human genes 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 5
- 230000009849 deactivation Effects 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 230000006798 recombination Effects 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 238000002525 ultrasonication Methods 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 108010033276 Peptide Fragments Proteins 0.000 claims description 4
- 102000007079 Peptide Fragments Human genes 0.000 claims description 4
- 210000004900 c-terminal fragment Anatomy 0.000 claims description 4
- 238000005352 clarification Methods 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000012678 infectious agent Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000002101 lytic effect Effects 0.000 claims description 4
- 239000002609 medium Substances 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000010257 thawing Methods 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 206010008631 Cholera Diseases 0.000 claims description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 2
- 108010028921 Lipopeptides Proteins 0.000 claims description 2
- 201000005702 Pertussis Diseases 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 238000012412 chemical coupling Methods 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000002077 nanosphere Substances 0.000 claims description 2
- 238000006386 neutralization reaction Methods 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 230000003071 parasitic effect Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 2
- 210000003705 ribosome Anatomy 0.000 claims description 2
- 229930182490 saponin Natural products 0.000 claims description 2
- 150000007949 saponins Chemical class 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 229960000814 tetanus toxoid Drugs 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 238000005538 encapsulation Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000007792 addition Methods 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- -1 Alhydrogel Chemical class 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention concerns the use of a membrane fraction of gram-negative bacteria, in particular Klebsiella pneumoniae combined with an antigen or hapten for preparing a pharmaceutical composition designed to direct the immune response towards a Th1 and/or a mixed Th1/Th2 type response directed against said antigen or hapten. The invention further concerns methods for preparing said membrane fractions and pharmaceutical compositions containing them and their uses for preventing and treating infectious diseases, in particular those involving paramyxovirus such as VRS, and cancers, in particular those with tumour-associated antigens.
Description
BACTERIAL MEMBRANE FRACTIONS WITH ADJUVANT EFFECT
: The present invention relates to the use of a membrane fraction of gram-negative bacteria, in particular of i 5 Klebsiella pneumoniae, combined with an antigen or hapten, for the preparation of a pharmaceutical composition intended for orienting the immune response toward a Thl type and/or mixed Thl/Th2 type response directed against said antigen or hapten. This invention comprises, in addition, methods for the preparation of said membrane fractions and the pharmaceutical } compositions containing them and their applications to the prevention and treatment of infectious diseases, in . particular infections caused by paramyxoviruses such as
RSV, and cancers, in particular those whose tumors are associated with tumor antigens.
Vaccination is an effective means for preventing or reducing in particular infections. The success of vaccination campaigns in this field has made it possible to extend the concept of vaccines to the fields of autoimmune diseases, cancer and fertility. On the other hand, vaccinating antigens alone are not always capable of inducing a rapid and sustained antibody response, which requires the presence of adjuvants, that is to say compounds which help (from the latin adjuvare: to help) them to induce such responses.
Adjuvants constitute a group of varied compounds with respect to their structure and their origin. There are thus, inter alia, in this category water-in-oil (incomplete Freund's adjuvant) or oil-in-water emulsions, compounds of bacterial origin such as lipopolysaccharide derivatives from Gram-negative bacteria and aluminum salts. Currently, only aluminum salts are used in humans as adjuvant for vaccine preparations.
Co
The development of an antibody response directed against an antigen requires a series of complex events. . It involves cells presenting the antigen, regulatory T lymphocytes (Th for T “helper”), and antibody-producing : 5 B lymphocytes. Two types of Th lymphocytes may be distinguished according to the profile of cytokines produced: type 1 Th lymphocytes producing IFN-y and
IL-2 and promoting the formation of IgG2a in mice, and type 2 Th lymphocytes producing IL-4, IL-5 and IL-10 with formation of IgGl in mice (Mosmann, T.R. and Sad
S. Immunol. Today 1996, 17:138). Moreover, it has been shown that, for the same given antigen, it is the adjuvant which orients toward the predominant isotype during the antibody response (Toellner K.-M. et al. J.
Exp. Med. 1998, 187:1193). Thus, it is known that aluminum salts, such as Alhydrogel, induce, in mice, an essentially Th2 type response and promote the formation of IgGl or even of IgE (Allison A.C. In Vaccine design ~ The role of cytokine networks Vol. 2393, 1-9 Plenum
Press 1997), which can pose problems in subjects with an allergic predisposition. Furthermore, according to the therapeutic target envisaged, a Thl or mixed (Thl/Th2) type response may be desired.
Thus, there is currently a need to have available novel adjuvants capable of inducing an immune response of the
Thl or mixed (Thl/Th2) type, preferably a mixed Thl/Th2 response for which the Thl response is close to or greater than the Th2Z response.
Surprisingly, the authors of the present invention have demonstrated particular properties of the membrane fraction of a gram-negative bacterium Klebsiella pneumoniae (called FMKp), in particular membrane fractions obtained by methods as described below in the examples. The authors have indeed discovered that said membrane fraction FMKp, combined with an antigen, not only had the capacity to increase the antibody response directed against said antigen but also had the capacity to reorient the cytokine response toward a Thl/Th2 profile, thus corresponding to the particular adjuvant : activity sought, this being regardless of the mode of administration of said membrane fractions. : 5
Thus, the subject of the present invention is the use of a membrane fraction of gram-negative bacteria, in particular of Klebsiella pneumoniae, combined with an antigen or hapten for orienting the immune response toward a Thl type and/or mixed Thl/Th2 type response directed against said antigen or hapten, or for the preparation of a pharmaceutical composition intended for orienting the immune response toward a Thl type } and/or mixed Thl/Th2 type response directed against said antigen or hapten.
By orientation of the immune response toward a Thi and/or mixed Thl/Th2 type response, there is preferred in particular orientation of the immune response which promotes the induction of a Thl response relative to the Thl/Th2 response obtained with the alum adjuvant.
By orientation of the immune response toward a Thl and/or mixed Thl/Th2 type response, there is more particularly preferred an orientation of the immune response which increases the titer of IgG2a antibodies directed against the associated antigen by a factor of at least 10, preferably of at least 25, 50 and 100 relative to the IgG2a titer obtained with the alum adjuvant.
In a particularly preferred manner, the immune response is oriented toward a Thl and/or mixed Thl/Th2 type response in which the Thl response is close to or greater than the Th2 response. The expression “close to” will be understood to mean a response which, when expressed as titer of IgG2Z2a antibodies directed against the associated antigen, 1s at least equal to 0.5 times, preferably at least equal to 0.75 times, the
: | | Ca titer of IgGl antibody directed against said antigen, with a titer of IgG antibody directed against the . associated antigen close to or greater than the titer of IgG antibody directed against the associated antigen : 5 obtained with the alum or Freund's adjuvant.
The invention also relates to the use according to the invention, characterized in that the membrane fraction comprises at least membrane fractions of two different strains of bacteria.
The expression membrane fraction of a bacterium 1is understood to mean, in the present invention, any purified or partially purified membrane fraction or extract obtained from a culture of said bacterium and whose method of preparation comprises at least a step of lysing the bacteria obtained after culture and a step of separating the fraction containing the membranes of said bacteria from the total lysate obtained after the lysis step, in particular by centrifugation or filtration.
The expression membrane fraction of the bacterium when said bacterium is Klebsiella pneumoniae 1s also understood to mean, in the present invention, protein
P40, an active fraction of the membrane fraction of
Klebsiella pneumoniae, having an amino acid sequence
SEQ ID No. 2, or one of its fragments.
According to the invention, the membrane fractions may be prepared according to methods known to a person skilled in the art, such as for example the method described by Haeuw J.F. et al. (Eur. J. Biochem, 255, 446-454, 1998).
According to a particular embodiment, the invention relates to a use according to the invention, characterized in that the membrane fraction is prepared by a method comprising the following steps:
. C5 a) culture of said bacteria in a culture medium allowing their growth followed by centrifugation - of said culture; b) where appropriate, deactivation of the lytic : 5 enzymes of the bacterial pellet obtained in step a), followed by centrifugation of the suspension obtained;
Cc) extraction and removal of nonmembrane proteins and of nucleic acids from the pellet obtained in step : 10 a) or b) by at least one cycle of washing the pellet in an extraction solution; d) digestion of the membrane pellet obtained in step
Cc) in the presence of proteolytic enzymes, followed by centrifugation; ee) at least one cycle of washing of the pellet obtained in step d) in physiological saline and/or in distilled water; and f) ultrasonication of the pellet obtained in step e).
Step b) of deactivation of the lytic enzymes of the bacterial pellet obtained in step a) may be carried out by any known methods of deactivation of enzymes, such as in particular by heating the resuspended bacterial pellet at a temperature preferably of close to 100°C or by adding an inhibitor of the activity of these enzymes.
Step c¢) of extraction and removal of the nonmembrane proteins and of the nucleic acids from the pellet obtained in step a) or b) may be carried out, for example, by at least one cycle of washing of the pellet in an extraction solution corresponding to the addition of a hypertonic solution (extraction solution), preferably a saline solution having a molarity of close to 1 M, followed, after a contact period which is sufficient for the desired effect, by centrifugation of the suspension obtained and removal of the supernatant obtained after said centrifugation, it being possible for this washing cycle to be repeated several times.
Ce
Step d) of digestion of the membrane pellet obtained in - step c¢) may be carried out in the presence of a . solution of proteolytic enzymes such as, for example, trypsin, chymotrypsin, or any known enzyme with - 5 proteolytic activity, the reaction conditions, pH of the solution, temperature and duration of the reaction, being preferably adjusted to the optimum conditions for the activity of the chosen enzymel(s), followed by centrifugation, it being possible for this digestion . 10 cycle to be repeated several times with the same enzyme, the same combination of enzymes or with a different enzyme for each digestion cycle performed.
Step e) of washing the pellet obtained in step d) is carried out by taking up the pellet in physiological saline or in distilled water followed, after a sufficient period of contact, by centrifugation, it being possible for this washing cycle to be repeated several times.
Finally step £) of ultrasonication of the pellet is intended in particular to disintegrate and homogenize the membrane fraction obtained at the end of step e).
The ultrasonication conditions (duration and intensity) will be determined by persons skilled in the art, for example, according to the quantity of membrane fraction to be treated.
According to another particular embodiment, the invention relates to a use according to the invention, characterized in that the membrane fraction is prepared by a method comprising the following steps: a) culture of said bacteria in a culture medium allowing their growth, followed, where appropriate, by centrifugation; b) freezing of the culture medium or of the pellet obtained in step a) followed by thawing and drying of the cells;
oo Co c) removal, by means of a DNase, of the nucleic acids from the dry cells obtained in step b) which have - been resuspended; d) grinding of the cells obtained in step c¢) and - 5 clarification of the suspension obtained; e) precipitation, in an acid medium, of the suspension obtained in step d) and removal of the } pellet; £) neutralization of the supernatant obtained in step } 10 e) containing the membrane suspension, followed by dialysis and concentration of the membrane suspension; and g) sterilization of the concentrated membrane suspension obtained in step f).
The thawing conditions in step b) of the method below will of course be determined by persons skilled in the art according to the initial quantity of pellet to be treated, preferably carried out at 4°C for at least 48 hours for the equivalent of 1 kg of dry cells.
In step c), the removal of the nucleic acids is carried out, for example, by the addition of a DNase, at a final concentration of 5 mg/ml of a cell suspension at a concentration equivalent to 5% of dry cells.
The grinding of the cells obtained in step c¢) may be carried out by means of any system or apparatus known to a person skilled in the art for grinding cells, such as presses or preferably such as grinding in a Manton
Gaulinet loop for 30 minutes.
The clarification of the suspension obtained after grinding may be carried out by means of any system or apparatus known to a person skilled in the art for the clarification of ground products of bacterial cells such as the Sharpless system.
Step e) of precipitation in acid medium of the suspension obtained in step d) may be carried out, for . example, with acetic acid. The precipitation is followed by the removal of the pellet by means of a - 5 Sharpless-type system and by recovering of the supernatant.
Step f) consists in a step in which the supernatant, obtained after precipitation in acid medium, is . 10 neutralized, diluted, dialyzed and then concentrated.
Finally, the last step consists in a step of sterilizing the membrane fraction concentrate obtained in the preceding step such as, for example, by heating at 121°C for about 35 minutes.
The invention particularly relates to the use according to the invention, characterized in that the membrane fraction 1s the Klebsiella pneumoniae protein P40 having the sequence SEQ ID No. 2, or one of these fragments.
The expression protein P40 fragment is understood to mean in particular any fragment having an amino acid sequence contained in the amino acid sequence of protein P40 capable of increasing a nonspecific immune response and/or capable of inducing an antitumor immune response, and comprising at least 5 amino acids, preferably at least 10 amino acids and more preferably at least 15 amino acids.
Of course, said protein P40, or its fragments, may be obtained by chemical synthesis or in the form of recombinant peptides.
The invention particularly relates to the use according to the invention, characterized in that said antigen or hapten is chosen from the antigens or haptens specific to an infectious agent, such as a virus, a bacterium, a fungus or a parasite, or from the antigens associated with tumor cells.
According to the invention, said antigens or haptens . 5 are preferably chosen from peptides, lipopeptides, polysaccharides, oligosaccharides, nucleic acids, lipids or any compound capable of specifically directing the immune response toward a Thl type and/or mixed Thl/Th2 type response against an antigen or . 10 hapten specific to an infectious agent or an antigen associated with a tumor cell.
Of course, said antigen or hapten, when it is of a peptide nature, may be obtained by chemical or recombinant synthesis.
The methods for preparing recombinant peptides are nowadays well known to persons skilled in the art and will not be developed in the present description. Among the cells which may be used for the production of these recombinant peptides, there may of course be mentioned bacterial cells (Olins P.O. and Lee S.C., 1993, Recent advances in heterologous gene expression in E. coli
Curr. Op. Biotechnology 4:520-525), but also yeast cells (Buckholz R.G., 1993, Yeast Systems for the
Expression of Heterologous Gene Products. Curr. Op.
Biotechnology 4:538-542), as well as animal cells, in particular mammalian cell cultures (Edwards C.P. and aruffo A., 1893, Current applications of COS cell based transient expression systems. Curr. Op. Biotechnology 4, 558-563) but also insect cells in which methods may be used involving for example baculoviruses (Luckow
V.A., 1993, Baculovirus systems for the expression of human gene products. Curr. Op. Biotechnology 4, 564-572).
The invention comprises, in addition, the use according to the invention, characterized in that said antigen or hapten is coupled or mixed with said membrane fraction,
in particular covalently coupled with at least one of the compounds contained in the membrane fraction.
In a preferred embodiment, the invention comprises the . 5 use according to the invention, characterized in that said antigen or hapten is covalently coupled with a supporting peptide to form a complex capable of binding ] specifically to mammalian serum albumin, preferably said supporting peptide is a peptide fragment derived . 10 from streptococcal G protein, in particular the
C-terminal fragment called BB.
Of course, said complex may be prepared by genetic recombination.
The chimeric or hybrid complex may be produced by recombinant DNA techniques by insertion or addition of a sequence encoding said antigen or hapten of a protein nature to a DNA sequence encoding said peptide fragment of the streptococcal G protein.
The methods for the synthesis of hybrid molecules include the methods used in genetic engineering for constructing hybrid polynucleotides encoding the desired polypeptide sequences. Reference may be advantageously made, for example, to the technique for producing genes encoding fusion proteins which is described by D.V. Goeddel (Gene expression technology,
Methods in Enzymology, Vol. 185, 3-187, 1990).
According to the present invention, the covalent coupling may be carried out by chemical synthesis. In a particular embodiment of the invention, it will be possible for one or more linking elements to be introduced into at least one of the compounds contained in the membrane fraction and/or in said antigen or hapten to facilitate the chemical coupling.
Preferably, said linking element introduced is an amino acid.
According to the invention, it is possible to introduce - 5 one or more linking elements, in particular amino acids, to facilitate the coupling reactions between a compound of the membrane fraction, and said antigen or } hapten. The covalent coupling between said compound of the membrane fraction and said antigen or hapten } 10 according to the invention may be achieved at the N- or
C-terminal end of said compound of the membrane fraction or of said antigen or hapten, if the latter are for example of a peptide nature. The bifunctional reagents allowing the coupling will be determined according to the end which is chosen for the coupling and the nature of said antigen or hapten to be coupled.
The invention also comprises the use according to the invention, characterized in that the coupling between said antigen, hapten or complex and at least one of the compounds contained in the membrane fraction is carried out by genetic recombination when said antigen, hapten or complex and said membrane compound are of a peptide nature.
The coupling between said antigen, hapten or complex, and at least one of the compounds contained in the membrane fraction may indeed be carried out by genetic recombination. It will be possible, for example, before extracting its membrane fraction, to transform said gram-negative bacterium beforehand with a vector containing a nucleic construct encoding an antigen of interest or said complex, such that the bacterium thus transformed expresses the antigen of interest or said complex attached to the membrane or anchored in the membrane of said bacterium. Such methods for expressing recombinant proteins attached to the membrane are well known and require, for example, the presence of a specific regulatory sequence, such as a signal peptide- © type sequence.
The subject of the invention is also the use according . 5 to the invention, characterized in that the pharmaceutical composition comprises, in addition, an agent which makes it possible to carry said membrane fraction associated with said antigen, hapten or complex in a form which makes it possible to enhance } 10 its stability and/or its immunogenicity, such as in the form of an oil-in-water or water-in-oil type emulsion, or in the form of a particle of the liposome, microsphere or nanosphere type or any type of structure allowing the encapsation and the presentation, in particulate form, of said membrane fraction associated with said antigen, hapten or complex.
The invention also relates to the use according to the invention, characterized in that said agent is chosen from aluminum salts, calcium salts, compounds of plant origin such as Quil A or saponin, or compounds of bacterial origin such as the derivatives of cholera, pertussis or tetanus toxoid or of the E. coli thermolabile toxin.
Also included in the present invention is the use according to the invention, characterized in that the pharmaceutical composition comprises, in addition, an agent which makes it possible to regulate the immune response induced by said membrane fraction combined with said antigen, hapten or complex.
Among said regulatory agents, cytokines, growth factors, hormones or cellular components such as nucleic acids, a protein of the family of heat shock proteins or ribosomes are in particular preferred.
The subject of the invention is also the use according to the invention, for the preparation of a pharmaceutical composition intended for the prevention or treatment of infectious diseases of viral, : bacterial, fungal or parasitic origin, or for the prevention or treatment of cancers, in particular : 5 cancers in which the tumors are associated with tumor antigens.
Among said infectious diseases of viral origin, the infectious diseases caused by paramyxoviruses, in . 10 particular by the parainfluenzae virus and more preferably by the respiratory syncytial virus (RSV) are particularly preferred.
In a particular embodiment, the use according to the invention 1s characterized in that said antigen associated with the membrane fraction comprises the peptide G2Na, a fragment of the G protein of the virus having an amino acid sequence SEQ ID No. 4, a peptide homologous to G2Na whose sequence exhibits at least 80%, preferably 90%, 95% and 99% identity, after alignment with the sequence SEQ ID No. 4, or the peptide G2Na or one of its homologs, covalently coupled with a C-terminal fragment (BB) of the streptococcal G protein to form a complex capable of binding to mammalian serum albumin, peptide BB as described in the documents Power et al., 1897 (Virology, 230, 155-166) and WO 96/14416.
The expression “percentage, degree or level of identity” between two nucleic acid or amino acid sequences for the purposes of the present invention is understood to mean a percentage of identical nucleotides or amino acid residues between the two sequences to be compared, obtained after the best alignment, this percentage being purely statistical and the differences between the two sequences being randomly distributed over their full length. The sequence comparisons between two nucleic acid or amino acid sequences are traditionally carried out by comparing these sequences after having aligned them in an optimum manner, said comparison being carried out by : segment or by “comparison window” to identify and compare the local regions of sequence similarity. The - 5 optimum alignment of the sequences for the comparison may be carried out either manually or by means of the local homology algorithm by Smith and Waterman (1981) [Ad. App. Math. 2:482]), by means of the local homology algorithm by Neddleman and Wunsch (1970) [J. Mol. Biol. } 10 48.443], by means of the method of search for similarity by Pearson and Lipman (1988) [Proc. Natl.
Acad. Sci. USA 85:2444), by means of computer software using these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics
Computer Group, 575 Science Dr., Madison, WI, or by the comparison software packages BLAST N or BLAST P).
The percentage identity between two nucleic acid or amino acid sequences is determined by counting these two sequences optimally aligned by the comparison window in which the region of the nucleic acid or amino acid sequence to be compared may comprise additions or deletions relative to the reference sequence for an optimum alignment between these two sequences. The percentage identity is calculated by determining the number of identical positions for which the nucleotide or the amino acid residue is identical between the two sequences, by dividing this number of identical positions by the total number of positions in the comparison window and by multiplying the result obtained by 100 in order to obtain the percentage identity between these two sequences.
For example, it will be possible to use the BLAST program, “BLAST 2 sequences”, available on the site http://www.ncbi.nlm.nih.gov/gorf/bl2.html, the parameters used being those given by default (in particular for the parameters “open gap penaltie”: 5, and “extension gap penaltie”: 2; the template chosen being for example the template “BLOSUM 62" proposed by the program), the percentage identity between the two : sequences to be compared being calculated directly by the program.
In another aspect, the invention relates to a method for preparing a membrane fraction of gram-negative bacteria, in particular Klebsiella pneumoniae, characterized in that it comprises the following steps: a) culture of said bacteria in a culture medium allowing their growth followed by centrifugation of said culture; b) where appropriate, deactivation of the lytic enzymes of the bacterial pellet obtained in step a), followed by centrifugation of the suspension obtained;
Cc) extraction and removal of nonmembrane proteins and of nucleic acids from the pellet obtained in step a) or b) by at least one cycle of washing the pellet in an extraction solution; d) digestion of the membrane pellet obtained in step ¢c) in the presence of protease enzymes, followed by centrifugation; e) at least one cycle of washing of the pellet obtained in step d) in physiological saline and/or in distilled water; and f) ultrasonication of the pellet obtained in step e).
The invention also comprises the method for preparing a membrane fraction of gram-negative bacteria, in particular Klebsiella pneumoniae, characterized in that it comprises the following steps: a) culture of said bacteria in a culture medium allowing their growth, followed, where appropriate, by centrifugation;
Claims (33)
-
- ’ 1. The use of a Klebsiella pneumoniae membrane fraction combined with an antigen or hapten for the preparation of a pharmaceutical composition intended to orient the immune response toward a Thl type and/or mixed Thl/Th2 type response directed against said antigen or hapten. : 10 2. The use as claimed in claim 1, characterized in that the membrane fraction comprises at least membrane fractions of two different bacterial strains.
- 3. The use as claimed in either of claims 1 and 2, characterized in that the membrane fraction is prepared by a method comprising the following steps: a) culture of said bacteria in a culture medium allowing their growth followed by centrifugation of said culture; b) where appropriate, deactivation of the lytic enzymes of the bacterial pellet obtained in step a), followed by centrifugation of the suspension obtained; c) extraction and removal of nonmembrane proteins and of nucleic acids from the pellet obtained in step a) or b) by at least one cycle of washing the pellet in an extraction solution; d) digestion of the membrane pellet obtained in step c¢) in the presence of protease enzymes, followed by centrifugation; e) at least one cycle of washing of the pellet obtained in step d) in physiological saline and/or in distilled water; and f) ultrasonication of the pellet obtained in step e).
- 4. The use as claimed in either of claims 1 and 2, characterized in that the membrane fraction is - prepared by a method comprising the following steps: : 5 a) culture of said bacteria in a culture medium allowing their growth, followed, where appropriate, by centrifugation; } b) freezing of the culture medium or of the pellet obtained in step a) followed by thawing and. 10 drying of the cells; c) removal, by means of a DNase, of the nucleic acids from the dry cells obtained in step b) which have been resuspended; d} grinding of the cells obtained in step c) and clarification of the suspension obtained; e) precipitation, in an acid medium, of the suspension obtained in step d) and removal of the pellet; f) neutralization of the supernatant obtained in step e) containing the membrane suspension, followed by dialysis and concentration of the membrane suspension; and g) sterilization of the concentrated membrane suspension obtained in step f).
- 5. The use as claimed 1n one of claims 1 to 4, characterized in that said antigen or hapten is chosen from the antigens or haptens specific to an infectious agent or from the antigens associated with tumor cells.
- 6. The use as claimed in claim 5, characterized in that said antigen or hapten 1s chosen from peptides, lipopeptides, polysaccharides, oligosaccharides, nucleic acids, lipids or any compound capable of specifically directing the Thl type and/or mixed Thl/Th2 type immune response against an antigen or hapten specific to an. - 25 = infectious agent or an antigen associated with a tumor cell.
- 7. The use as claimed in one of claims 1 to 6, . 5 characterized in that said antigen or hapten is coupled or mixed with said membrane fraction.
- 8. The use as claimed in one of claims 1 to 7, characterized in that said antigen or hapten is } 10 covalently coupled with a supporting peptide to form a complex capable of specifically binding to mammalian serum albumin.
- 9. The use as claimed in claim 8, characterized in that said supporting peptide is a peptide fragment derived from streptococcal G protein.
- 10. The use as claimed in either of claims 8 and 9, characterized in that said complex is prepared by genetic recombination.
- 11. The use as claimed in one of claims 7 to 10, characterized in that said antigen, hapten or complex 1s covalently coupled with at least one of the compounds contained in the membrane fraction.
- 12. The use as claimed in claim 11, characterized in that the covalent coupling is a coupling carried out by chemical synthesis.
- 13. The use as claimed in claim 12, characterized in that there are introduced one or more linking elements into at least one of the compounds contained in the membrane fraction and/or in said antigen, hapten or complex to facilitate the chemical coupling.: : - 26 ~
- 14. The use as claimed in claim 13, characterized in that said linking element introduced is an amino
- . acid. : 5 15. The use as claimed in claim 11, characterized in that the coupling between said antigen, hapten or complex and at least one of the compounds contained in the membrane fraction is carried out by genetic recombination when said antigen, hapten or complex and said membrane compound are of a peptide nature.
- 16. The use as claimed in one of claims 1 to 15, characterized in that the pharmaceutical composition comprises, in addition, an agent which makes it possible to carry said membrane fraction associated with said antigen, hapten or complex in a form which makes it possible to enhance its stability and/or its immunogenecity.
- 17. The use as claimed in claim 16, characterized in that said agent is an oil-in-water or water-in-oil type emulsion.
- 18. The use as claimed in claim 16, characterized in that said agent is a particle of the liposome, microsphere or nanosphere type or any type of structure allowing the encapsulation and the presentation in particulate form of said membrane fraction associated with said antigen, hapten or complex.
- 19. The use as claimed in claim 16, characterized in that said agent is chosen from aluminum salts, calcium salts, compounds of plant origin such as Quil A or saponin, or compounds of bacterial origin such as cholera, pertussis or tetanus toxoid or thermolabile E. coli toxin.
- 20. The use as claimed in claims 1 to 19, character- ized in that the pharmaceutical composition - comprises, in addition, an agent which makes it possible to regulate the immune response induced : 5 by said membrare fraction associated with said antigen, hapten or complex. }
- 21. The use as claimed in claim 20, characterized in that said regulatory agent is chosen from } 10 cytokines, growth factors, hormones or cellular components such as nucleic acids, a protein of the family of heat shock proteins or ribosomes.
- 22. The use as claimed in one of claims 1 to 21, for the preparation of a pharmaceutical composition intended for the prevention or treatment of infectious diseases or cancers.
- 23. The use as claimed in claim 22, characterized in that the infectious disease is of viral, bacterial, fungal or parasitic origin.
- 24. The use as claimed in claim 23, for the preparation of a pharmaceutical composition intended for the prevention or treatment of paramyxovirus infections.
- 25. The use as claimed in claim 24, characterized in that the paramyxovirus is a respiratory syncytial virus.
- 26. The use as claimed in claim 25, characterized in that said antigen associated with the membrane fraction comprises the peptide G2Na having the sequence SEQ ID No. 4 or one of its homologs whose sequence exhibits a degree of identity of at least 80% with the sequence SEQ ID No. 4.
- 27. The use as claimed in claim 26, characterized in that said peptide G2Na or one of its homologs is . covalently coupled with a C-terminal fragment (BB) of the streptococcal G protein to form a complex : 5 capable of binding to mammalian serum albumin.
- 28. The use as claimed in claim 24, characterized in that the paramyxovirus 1s a parainfluenzae virus. } 10
- 29. A pharmaceutical composition, «characterized in that it comprises a membrane fraction prepared by the method as defined in either of claims 3 and 4, and an antigen or hapten associated with said membrane fraction.
- 30. The pharmaceutical composition as claimed in claim 29, characterized in that said antigen is chosen from paramyxovirus peptide fragments.
- 31. The pharmaceutical composition as claimed in claim 30, characterized in that the paramyxovirus is a respiratory syncytial virus or a parainfluenzae virus.
- 32. The pharmaceutical composition as claimed in claim 31, characterized in that said antigen associated with the membrane fraction comprises the peptide G2Na having the sequence SEQ ID No. 4 of the respiratory syncytial virus or a peptide whose sequence exhibits a degree of identity of at least 80% with the sequence SEQ ID No. 4.
- 33. The pharmaceutical composition as claimed in claim 32, characterized in that said peptide G2Na or one of 1ts homologs is covalently coupled with a C-terminal fragment (BB) of the streptococcal G protein to form a complex capable of binding to mammalian serum albumin.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9903153A FR2790959B1 (en) | 1999-03-15 | 1999-03-15 | USE OF BACTERIAL MEMBRANARY FRACTIONS WITH ADJUVANT EFFECT, THEIR PREPARATION METHODS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200107628B true ZA200107628B (en) | 2002-07-22 |
Family
ID=9543184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200107628A ZA200107628B (en) | 1999-03-15 | 2001-09-17 | Bacterial membrane fractions with adjuvant effect. |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1158993B1 (en) |
JP (1) | JP2002539169A (en) |
CN (1) | CN1151799C (en) |
AT (1) | ATE346602T1 (en) |
AU (1) | AU778957B2 (en) |
BR (1) | BR0009051A (en) |
CA (1) | CA2367917A1 (en) |
DE (1) | DE60032119T2 (en) |
ES (1) | ES2276673T3 (en) |
FR (1) | FR2790959B1 (en) |
WO (1) | WO2000054789A1 (en) |
ZA (1) | ZA200107628B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2822071B1 (en) * | 2001-03-15 | 2005-07-01 | Pf Medicament | USE OF A MEMBRANE FRACTION OF GRAM NEGATIVE BACTERIA TO INDUCE THE MATURATION OF DENDRITIC CELLS |
NZ552583A (en) | 2004-06-15 | 2009-09-25 | New York Blood Ct Inc | Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus |
WO2012166458A1 (en) | 2011-05-27 | 2012-12-06 | Lexicon Pharmaceuticals, Inc. | 4h-thieno[3,2-c]chromene-based inhibitors of notum pectinacetylesterase and methods of their use |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2596064B1 (en) * | 1986-03-18 | 1990-02-02 | Pf Medicament | INDUSTRIAL PROCESSES FOR THE MANUFACTURE OF RIBOSOMAL VACCINES AND RIBOSOMAL VACCINES OBTAINED |
CA1331355C (en) * | 1986-04-21 | 1994-08-09 | Bioenterprises Pty. Ltd | Immunopotentation |
FR2718452B1 (en) * | 1994-04-06 | 1996-06-28 | Pf Medicament | Element of immunogen, immunogenic agent, pharmaceutical composition and method of preparation. |
FR2726472B1 (en) * | 1994-11-07 | 1997-01-31 | Pf Medicament | CARRIER WITH ADJUVANT EFFECT, IMMUNOGENIC COMPLEX CONTAINING THE SAME, PREPARATION METHOD THEREOF, NUCLEOTIDE SEQUENCE AND VACCINE |
FR2748476B1 (en) * | 1996-05-07 | 1998-08-14 | Pf Medicament | IMMUNOGENIC COMPLEX, ITS USE, ITS PREPARATION METHOD AND VACCINE CONTAINING THE SAME |
FR2766192B1 (en) * | 1997-07-17 | 2001-07-13 | Pf Medicament | EPITOPES OF RSV AND ANTIBODIES COMPRISING SAME, USEFUL IN DIAGNOSIS AND THERAPY |
CN1174099C (en) * | 1997-07-18 | 2004-11-03 | 康诺特实验室有限公司 | Nucleic acid vaccines encoding G protein of respiratory syncytial virus |
FR2785542B1 (en) * | 1998-11-06 | 2001-02-09 | Pf Medicament | USE OF AN ENTEROMACTERY OmpA PROTEIN FOR THE SPECIFIC TARGETING OF A BIOLOGICALLY ACTIVE SUBSTANCE THAT IS ASSOCIATED WITH CELLS PRESENTING ANTIGENS SUCH AS HUMAN DENDRITIC CELLS |
-
1999
- 1999-03-15 FR FR9903153A patent/FR2790959B1/en not_active Expired - Fee Related
-
2000
- 2000-03-15 CN CNB008050449A patent/CN1151799C/en not_active Expired - Fee Related
- 2000-03-15 AU AU32980/00A patent/AU778957B2/en not_active Ceased
- 2000-03-15 ES ES00910946T patent/ES2276673T3/en not_active Expired - Lifetime
- 2000-03-15 JP JP2000604864A patent/JP2002539169A/en active Pending
- 2000-03-15 AT AT00910946T patent/ATE346602T1/en not_active IP Right Cessation
- 2000-03-15 EP EP00910946A patent/EP1158993B1/en not_active Expired - Lifetime
- 2000-03-15 CA CA002367917A patent/CA2367917A1/en not_active Abandoned
- 2000-03-15 BR BR0009051-4A patent/BR0009051A/en not_active Application Discontinuation
- 2000-03-15 WO PCT/FR2000/000622 patent/WO2000054789A1/en active IP Right Grant
- 2000-03-15 DE DE60032119T patent/DE60032119T2/en not_active Expired - Fee Related
-
2001
- 2001-09-17 ZA ZA200107628A patent/ZA200107628B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2000054789A1 (en) | 2000-09-21 |
FR2790959B1 (en) | 2003-06-27 |
ES2276673T3 (en) | 2007-07-01 |
DE60032119D1 (en) | 2007-01-11 |
CN1343124A (en) | 2002-04-03 |
EP1158993B1 (en) | 2006-11-29 |
CN1151799C (en) | 2004-06-02 |
DE60032119T2 (en) | 2007-09-27 |
EP1158993A1 (en) | 2001-12-05 |
JP2002539169A (en) | 2002-11-19 |
AU778957B2 (en) | 2004-12-23 |
CA2367917A1 (en) | 2000-09-21 |
ATE346602T1 (en) | 2006-12-15 |
FR2790959A1 (en) | 2000-09-22 |
AU3298000A (en) | 2000-10-04 |
BR0009051A (en) | 2002-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bowersock et al. | Oral vaccination with alginate microsphere systems | |
RU2211050C2 (en) | Vaccines with ltb adjuvant | |
AU771205B2 (en) | Novel, non-antigenic, mucosal adjuvant formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces | |
WO2007113633A2 (en) | Immunogenic compositions comprising cat allergen fel dl | |
CN101094686A (en) | Use of flagellin in tumor immunotherapy | |
ZA200107628B (en) | Bacterial membrane fractions with adjuvant effect. | |
KR100649286B1 (en) | Vaccine preparations containing attenuated toxin | |
Kozuka et al. | Efficient extracellular production of recombinant Escherichia coli heat-labile enterotoxin B subunit by using the expression/secretion system of Bacillus brevis and its mucosal immunoadjuvanticity | |
MXPA01009346A (en) | Bacterial membrane fractions with adjuvant effect | |
Rupa et al. | Engineered recombinant ovomucoid third domain can modulate allergenic response in Balb/c mice model | |
Gebara et al. | Adjuvant and immunogenic activities of the 73 kDa N-terminal α-domain of BrkA autotransporter and Cpn60/60 kDa chaperonin of Bordetella pertussis | |
US10232036B2 (en) | Vaccine formulation, preparation method therefor and use thereof | |
WO2020203731A1 (en) | Pneumococcal surface proteins | |
CA2382331C (en) | Vaccine against intra-cellular pathogens | |
RU2818278C2 (en) | Pneumococcal surface proteins | |
US7125696B2 (en) | Method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent | |
Stokes | Biotechnology and animal health | |
STOKES | Langford House, Langford, Bristol BS18 7DU | |
US20020106376A1 (en) | Therapeutic or prophylactic composition of fibronectin-binding protein 1 (SFBI) as adjuvant | |
MXPA97001445A (en) | Effective mutating enterotoxin as adjuvant oral no tox | |
MXPA00005127A (en) | Vaccines with an ltb adjuvant | |
MX2009013222A (en) | Adjuvant compositions based on salmonella enterica serovar typhi omps2 porins. | |
AU2005204218A1 (en) | Vaccine Against Intra-Cellular Pathogens |